Cereno Scientific’s Phase II study in the rare disease PAH reports two patients successfully completed the treatment period with drug candidate CS1
Cereno Scientific (XSAT: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that two patients have successfully completed the treatment period in the study. The study is proceeding according to plan and top-line results are anticipated at year-end 2023.“We are happy to see further progress in the Phase II study with CS1; recruitment is still a major focus, however, equally important is that patients are able to successfully complete the study treatment period with CS1,” Björn Dahlöf, CMO at Cereno. “I am pleased with the